论文部分内容阅读
目的观察氯吡格雷、厄贝沙坦与黄芪饮片三者联用治疗糖尿病肾病(DN)的临床疗效。方法将50例DN患者随机分为治疗组和对照组各25例。2组均采用DM基础治疗,在此基础上,治疗组给予氯吡格雷、厄贝沙坦与黄芪饮片三联治疗;对照组单用厄贝沙坦,检测2组治疗前后血尿素氮(BUN)、肌酐(SCr)、24 h尿白蛋白(Alb)定量及空腹血糖(FBG)水平。结果治疗后2组患者24 h尿Alb定量均较治疗前明显改善,治疗组SCr、BUN较治疗前明显改善,治疗组24 h尿Alb定量、SCr、BUN下降幅度明显大于对照组,差异有统计学意义(P<0.05)。2组治疗前后FBG变化无明显差异(P>0.05)。在治疗期间均未出现因使用厄贝沙坦、氯吡格雷和黄芪饮片发生的不良反应。结论氯吡格雷、厄贝沙坦与黄芪饮片三联治疗DN比单用厄贝沙坦效果更佳。
Objective To observe the clinical efficacy of combination therapy of clopidogrel, irbesartan and astragalus tablets in treating diabetic nephropathy (DN). Methods 50 patients with DN were randomly divided into treatment group and control group, 25 cases each. 2 groups were treated with DM, on this basis, the treatment group was given clopidogrel, irbesartan and astragalus Pieces triple therapy; control group with irbesartan, two groups before and after treatment to detect blood urea nitrogen (BUN) , Creatinine (SCr), 24 h urinary albumin (Alb) and fasting blood glucose (FBG). Results After 24 hours of treatment, urinary Alb in both groups were significantly improved compared with that before treatment. The SCr and BUN in the treatment group were significantly improved compared with those before treatment. The urinary Alb quantification, SCr and BUN in the 24-hour treatment group decreased more significantly than those in the control group Significance (P <0.05). There was no significant difference in FBG changes between the two groups before and after treatment (P> 0.05). During the treatment did not appear due to the use of irbesartan, clopidogrel and Astragalus Pieces occurred adverse reactions. Conclusion Clopidogrel, Irbesartan and Astragalus Pieces triple therapy DN better than irbesartan alone better.